IceCure Medical Ltd. (ICCM) on Wednesday, has reported favorable top-line results from its ICESECRET clinical trial, which assessed the ProSense Cryoablation System for the treatment of small renal masses in patients with kidney cancer.
The trial included 114 participants, with 112 patients evaluated at a median follow-up period of four years, demonstrating an 83.9 percent rate of recurrence-free survival.
Among a subgroup of patients with tumors measuring 3 cm or smaller, who had no prior history of kidney cancer and underwent successful initial treatment, the recurrence free survival rate reached 89.4 percent.
ICCM is currently trading at $0.59, down $0.0157 or 2.58 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.